Histogenics to lay off 65% of workforce, including CMO & CBO, in restructuring

Histogenics (NSDQ:HSGX) said today that its board of directors approved a restructuring plan with a 65% reduction in its workforce, including the the company’s chief medical officer Dr. Lynne Kelley and chief business officer Donald Haut, according to an SEC filing.